Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 520.50M | 616.56M | 624.29M | 440.52M | 318.72M | 94.09M |
Gross Profit | 169.62M | 197.69M | 195.38M | 154.72M | 109.75M | 31.35M |
EBITDA | 15.34M | 45.80M | 31.75M | 32.40M | 28.07M | -9.25M |
Net Income | -640.62K | 19.99M | 6.86M | 34.58M | 23.74M | -14.80M |
Balance Sheet | ||||||
Total Assets | 430.79M | 455.62M | 490.45M | 393.28M | 309.60M | 100.17M |
Cash, Cash Equivalents and Short-Term Investments | 79.01M | 89.24M | 59.29M | 157.34M | 175.54M | 32.42M |
Total Debt | 60.86M | 57.19M | 46.50M | 19.91M | 16.51M | 13.89M |
Total Liabilities | 128.87M | 140.44M | 185.28M | 114.35M | 82.55M | 33.23M |
Stockholders Equity | 309.34M | 320.92M | 300.79M | 273.23M | 219.58M | 55.00M |
Cash Flow | ||||||
Free Cash Flow | 84.34M | 64.50M | -74.35M | 23.37M | -8.60M | -16.97M |
Operating Cash Flow | 90.63M | 70.34M | -64.22M | 28.87M | -1.95M | -10.65M |
Investing Cash Flow | -14.91M | -12.72M | -29.88M | -38.45M | -8.59M | -6.04M |
Financing Cash Flow | -31.79M | -24.15M | 1.12M | -6.18M | 155.21M | -812.09K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | $463.46M | 166.47 | 2.52% | ― | 25.02% | ― | |
58 Neutral | $465.54M | 10.98 | 9.93% | ― | 6.97% | ― | |
52 Neutral | $150.64M | 12.68 | -0.21% | ― | -26.00% | -103.18% | |
52 Neutral | $533.30M | ― | -12.03% | ― | 12.19% | -1.59% | |
51 Neutral | $7.55B | 0.39 | -61.90% | 2.32% | 17.14% | 1.55% | |
51 Neutral | $488.27M | ― | 39.18% | ― | 1.05% | -288.07% | |
43 Neutral | $45.57M | ― | -131.17% | ― | 9.79% | -47.01% |
On June 17, 2025, DocGo Inc. held its Annual Meeting of Stockholders, where several key decisions were made. The election of three Class I directors was confirmed, and the compensation of named executive officers was approved on a non-binding basis. However, amendments to the company’s charter regarding corporate opportunities and officer exculpation were not approved. Additionally, the appointment of Urish Popeck & Co., LLC as the independent registered public accounting firm for 2025 was ratified.
The most recent analyst rating on (DCGO) stock is a Hold with a $2.85 price target. To see the full list of analyst forecasts on DocGo stock, see the DCGO Stock Forecast page.
On June 12, 2025, DocGo Inc. announced an extension of its share repurchase program’s expiration date from June 30, 2025, to December 31, 2025, allowing the company to continue purchasing up to $26 million in common stock. This extension provides the company with flexibility to repurchase shares based on market conditions and other factors, potentially impacting its stock value and benefiting shareholders.
The most recent analyst rating on (DCGO) stock is a Hold with a $2.85 price target. To see the full list of analyst forecasts on DocGo stock, see the DCGO Stock Forecast page.